Interestingly, the administration of a monoclonal antibody directed against p40, which represents the common subunit of IL-23 and IL-12, was effective in both phases of anti-MPO GN [91], providing experimental evidence for a treatment option in autoimmune GN. Here, MPO is linked to ganglioneuroma.